April 2005
How Patients Can Benefit From Molecular Imaging
Paula M. Jacobs, Ph.D
Vice President
Advanced Magnetics, Inc
April 2005
How Patients Can Benefit From Molecular Imaging
• Probe basic biological and disease processes in animal models– Identify therapeutic targets
– Identify prognostic factors
• Provide new clinical imaging agents for– Diagnosis
– Therapeutic stratification
– Monitor response to therapy
April 2005
MR Agent Development
• $50 M minimum and at least 10 years to develop a single diagnostic indication
• Reimbursement now around $45/dose
• Might be able to charge $100-200/dose
• About 1 million patients a year to even think about breaking even
• Example: 10-12,000 new high grade glioma patients each year
April 2005
Barriers to clinical availability of imaging
agents• Small potential patient populations but
ever increasing regulatory requirements
• Expensive pre-clinical & manufacturing investment before trials
• Unpredictable regulatory climate
• Difficult reimbursement climate
Poor commercial viability
April 2005
What can we do to make these targeted imaging agents
available to small but important patient
populations?